Video

Conference Coverage From the 2012 ESMO Congress

Author(s):

Onclive Team
Conference|ESMO Congress

Coverage from the 2012 European Society for Medical Oncology congress, held at the Austria Center Vienna from September 28 - October 2, in Vienna, Austria.

OncLive presents live coverage from the 2012 European Society for Medical Oncology (ESMO) congress, held at the Austria Center Vienna from September 28 to October 2, in Vienna, Austria.

ESMO is a large European professional organization committed to furthering oncology care and treatment through the dissemination of research and data.The 2012 installment of the ESMO meeting highlights advances in multiple tumor types, including information on targeted agents for lung cancer, melanoma, and gastrointestinal cancers.

OncLive’s conference coverage features video interviews with leading oncologists and articles discussing the latest breaking news and clinical trial results presented at the meeting.

For more information on ESMO, visit esmo.org.

Not signed up to receive OncLive emails? Make an account today to make sure that you don't miss updates from our conference coverage. Register now!

<<<

View coverage from the 2012 ESMO Congress

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School
Nicolas Girard, MD, professor, respiratory medicine, Versailles Saint Quentin University; head, Curie-Montsouris Thorax Institute, chair, Medical Oncology Department, Institut Curie
Related Content
Meredith McKean, MD
October 17th 2024

Experts Highlight Noteworthy Research From the 2024 ESMO Congress

Jay Detsky, MD, PhD, FRCP
October 11th 2024

MR-Linac Radiotherapy Limits Target Volume, Brain Tissue Exposure in High-Grade Glioma

Kenneth W. Merrell, MD
October 9th 2024

PFS Data for 177Lu-Dotatate Surpass Clinical Benchmarks in Refractory Meningioma

John Michael Bryant, MD
October 8th 2024

Nivolumab Plus Radiotherapy Reduces Rates of Biochemical Recurrence in Gleason Grade 5 Prostate Cancer

Kristin A. Higgins, MD, chief clinical officer, City of Hope Cancer Center Atlanta
October 6th 2024

Atezolizumab Plus Chemoradiation Provides No Survival Benefit in LS-SCLC

Neha Korde, MD, of Memorial Sloan Kettering Cancer Center
October 2nd 2024

MRD Negativity Is Sustained After Cessation of Lenalidomide Maintenance in Multiple Myeloma